The role of next-generation sequencing in the diagnosis of 

lysosomal storage disorders by Komlósi, Katalin et al.
The role of next-generation sequencing in the diagnosis of  
lysosomal storage disorders 
 
Katalin Komlosi
1,2
, Alexander Sólyom3, Michael Beck2 
1Institute of Medical Genetics, University of Pécs, Pécs, Hungary 
2
Institute of Human Genetics, University Medical Center, Johannes Gutenberg University 
Mainz, Mainz, Germany 
3 
Clinical Research, Plexcera Therapeutics LLC, New York, NY, USA 
Corresponding author: 
Katalin Komlosi, MD, PhD 
Institute of Medical Genetics 
University of Pécs 
Szigeti street 12. 
H-7624 Pécs 
Hungary 
Phone: +36 (72) 535-978 
Fax: +36 (72) 535-978 
e-mail: komlosi.katalin@pte.hu 
 
Key words: NGS, LSD, target enrichment, coverage, clinical utility 
 
Abbreviations: 
LSD-lysosomal storage disorders 
NGS-next-generation sequencing 
WES-whole exome sequencing 
WGS-whole genome sequencing 
 
 
 
 
Abstract 
Next-generation sequencing (NGS) panels are used widely in clinical diagnostics to identify 
genetic causes of various monogenic disease groups including neurometabolic disorders and, 
more recently, lysosomal storage disorders. Many new challenges have been introduced 
through these new technologies, both at the laboratory level and at the bioinformatics level, 
with consequences including new requirements for interpretation of results, and for genetic 
counseling. We review some recent examples of the application of NGS technologies, with 
purely diagnostic and with both diagnostic and research aims, for establishing a rapid genetic 
diagnosis in lysosomal storage disorders. Given that NGS can be applied in a way that takes 
into account the many issues raised by international consensus guidelines, it can have a 
significant role even early in the course of the diagnostic process, in combination with 
biochemical and clinical data. Besides decreasing the delay in diagnosis for many patients, a 
precise molecular diagnosis is extremely important as new therapies are becoming available 
within the LSD disease spectrum for patients who share specific types of mutations. A genetic 
diagnosis is also the prerequisite for genetic counseling, family planning and the individual 
choice of reproductive options in affected families. 
 
Introduction 
Next-generation sequencing, also referred to as massively parallel sequencing, is a high-
throughput DNA sequencing technology that enables the fast generation of data on thousands 
to millions of base pairs of DNA from an individual patient by sequencing large numbers of 
genes in a single reaction.
1
 The rapid emergence and huge success of these technologies in the 
research field paved the way for a new era in genetic diagnostics. Next-generation sequencing 
(NGS) panels are used widely in clinical diagnostics to identify genetic causes of various 
monogenic disease groups, such as epilepsy,
2
 intellectual disability,
3,4
 neurodevelopmental 
disorders,
5
 and neurometabolic disorders,
6
 among others. However, many new challenges 
have been introduced through these new methods, both at the technical level and at the 
bioinformatic level, with consequences including new requirements for interpretation of 
results, and for genetic counseling. In order to define the precise role of NGS in diagnostics, 
consensus guidelines have been proposed which mostly deal with NGS testing for rare and 
monogenic diseases.
7
 
 
Lysosomal storage diseases (LSDs) are a group of rare diseases in which a genetic mutation 
leads to the accumulation of specific macromolecules which impair the function of the 
lysosome often causing secondary disturbances in other cellular and metabolic processes. 
With a combined incidence of ~1 in 1500 to 7000 live births, they encompass >50 different 
entities.
8
 Unfortunately, there is considerable clinical variability within each disease 
phenotype, and also overlaping symptomatology among LSDs which hampers the precise 
diagnosis of these disorders.
9
 This makes a diagnosis solely based on the clinical presentation 
difficult in many cases. 
In the past, many methods have been used to approach a diagnosis in the LSDs.
10
 Laboratory 
assays based on identification or quantification of the storage products have been one of the 
most favored methods. Tests for elevated secreted substrate material are routinely used to 
screen for glycosaminoglycans and oligosaccharides in patients suspected of having 
mucopolysachharidoses and disorders that present with oligosacchariduria. The urine screens 
are usually very sensitive, however, affected individuals with normal urine screens and 
healthy individuals with elevated excretions have been reported.
11
 The second main pillar of 
establishing a diagnosis in LSDs are enzyme activity measurements. Enzyme activity detected 
in dried blood spots is very useful in the diagnosis of a small number of LSDs , however, this 
method usually requires verification with a second type of assay. Measurement of enzyme 
activity in leukocytes, plasma or fibroblasts is often a logistic and technical problem, with 
particular storage and transport requirements as well as laboratory expertise. Enzyme 
activities are usually not reliable in detecting heterozygous carriers of a disease. While 
biochemical methods are still the gold-standard of diagnosis, they are often very laborious, 
time-consuming and require a pre-selection by clinical phenotype to reduce the number of 
biochemical tests used for each patient suspected of LSDs.
12
 Diagnosis of LSDs is still a 
clinical challenge and can often take several years. 
Even having achieved a diagnosis with traditional assays, establishing a molecular genetic 
diagnosis is still important for several reasons. The precise molecular diagnosis is of great 
importance in the LSDs as new therapies are becoming available for specific types of LSDs, 
and for patients who share specific types of mutations.
9,13
 The complexity underlying the 
pathogenesis of LSDs and the small population of patients, who are many times children, 
make the development of therapies for these diseases challenging. Current treatments are only 
available for a small subset of LSDs and have, for the most part, not been effective at treating 
or preventing neurological symptoms. Clinical trials have demonstrated some clinical benefit 
of enzyme replacement therapy in Gaucher disease, Fabry disease, mucopolysaccharidoses 
type I, II, IV, VI, VII and in Pompe disease. However, the usefulness of enzyme replacement 
therapy is limited due to the fact that a given enzyme preparation does not have beneficial 
effects on all aspects of a disorder to the same degree. The effectiveness of each therapy is 
determined by whether the symptoms it affects are those which are most important to the 
patients’ overall health and quality of life. Additionally, clinical studies have shown that the 
pathologic changes underlying many symptoms of a lysosomal storage disorder are not 
reversible, even with long-term treatment.
9
 Thus, a precise molecular diagnosis early in the 
course of the disease can be of great significance. A definitive diagnosis is also the 
prerequisite for patients to have access to studies of newly developed therapeutic strategies, 
such as small molecules for substrate reduction or for enzyme enhancing therapy.
9,13
 
 
The application of NGS in the diagnosis of LSDs: overview of the literature 
 
Studies of purely diagnostic targeted NGS panels 
As outlined above, there are many factors hampering the diagnosis of LSDs, among others the 
phenotypic and penetrance variability, common signs and symptoms between certain disease 
groups, the genetic heterogeneity in some forms and the difficulties of biochemical 
diagnostics. The application of a broad diagnostic tool could enhance the sometimes very long 
diagnostic process for the affected families and thereby grant quicker access to current and 
investigated therapeutic options while providing the basis for more appropriate genetic 
counseling. There is only scarse published data on the application of next-generation 
sequencing in the diagnostics of lysosomal storage disorders. 
The recent study by Fernandez-Marmiesse et al
12
 reports for the first time the results of a pilot 
project to evaluate the application of NGS to mutation screening in the diagnosis of lysosomal 
storage disorders. With the help of a next-generation sequencing-based approach for the 
simultaneous analysis of 57 lysosomal genes they were able to correctly diagnose 18 positive 
blinded controls and provide genetic diagnosis to 25 patients with a high to moderate clinical 
suspicion index for LSDs from Spain and Portugal. In their study they analyzed 84 probands, 
including 18 positive controls in whom biochemical testing and Sanger sequencing had 
already ascertained a diagnosis of LSD and 66 patients with a suspected LSD. They used a 
custom Sure Select oligonucleotide probe library to capture all coding exons and exon-intron 
boundaries of 57 genes known to be associated with LSDs according to GeneReviews.
12
 
Sequencing was performed on SOLiD4 and HiSeq2000 Illumina platforms, with the latter 
yielding better coverage (99,97% of bases covered by at least 20 reads and only 0,03% of 
target bases with a coverage of less than 20 reads). As to the technical difficulties 
encountered, the authors emphasize that two factors limit enrichment. The local sequence 
architecture has a strong effect on the efficiency of DNA enrichment for individual exons,
14
 
so that exons close to repetitive regions are not fully covered. For exons located in CpG 
islands (high frequency of CpG sites: regions of DNA where a cytosine nucleotide is followed 
by a guanine nucleotide in the linear sequence of bases along its 5'→3' direction), coverage 
also decreased dramatically, producing gaps in coverage of certains exons of LSD genes, 
mostly in IDUA, GBA and GAA genes. The problem was overcome, however, with a greater 
overall coverage achieved on the HiSeq platform. To establish an NGS-LSD assay as a 
diagnostic tool for routine use it is essential to eliminate sequence gaps in order not to miss 
mutations in certain exons.
12
 
The authors also point out the difficulties encounterd with data filtering and interpretation in 
the NGS assay. One of the main challenges of using NGS for diagnostic applications is the 
interpretation of a massive number of genomic variants detected by sequencing platforms. 
Coverage irregularities contributed to false-positive variants. Thus, by improving enrichment 
efficacy or increased coverage, false-positive variants can be largely avoided. Efficient and 
reliable identification of causative variants is crucial to the implementation of this technology 
in routine diagnostics. The authors conclude that they would not propose thair assay as the 
sole diagnostic tool, but as a useful adjunct to diagnosis for specialists in the clinical 
management of LSD patients especially given its advantage to provide accurate information 
in a short time.
12
 
Another example for the clinical utility of gene panels in the diagnosis of lysosomal storage 
disorders is the diagnosis of late-onset Pompe disease by a next-generation sequencing 
approach published by Lévesque et al. in 2016.15 The authors developed a gene panel to 
analyze the coding sequences and splice site junctions of the GAA gene along with 77 other 
genes causing muscle disorders with overlapping phenotypes. They achieved a median 
coverage of 200X with all GAA exons successfully covered with >20X and only 0,3% of 
exons across all genes in the panel were <20X. Using known variants in Pompe patients and 
controls the authors could demonstrate an excellent sensitivity (100%) and specificity (98%) 
across all selected genes. Analyzing 34 patients with suspected muscle disorders of unknown 
etiology the study could show a detection rate of 32%. Especially in patients with an atypical 
presentation, including one late-onset Pompe disease case, the gene panel was instrumental in 
reaching a diagnosis. In all diagnosed patients biochemical testing (acid alpha-glucosidase 
activity) confirmed the molecular results. The NGS panel was shown to facilitate the 
diagnosis in patients showing non-specific muscle weakness or atypical phenotypes.
15
 
 
Diagnostic and research NGS panels to detect LSDs 
According to the „Guidelines for diagnostic next-generation sequencing” on behalf of the 
EuroGentest and the European Society of Human Genetics
7
: „for diagnostic purpose, only 
genes with a known (ie, published and confirmed) relationship between the aberrant genotype 
and the pathology should be included in the analysis” of NGS assays. However, several 
applications with a research focus have ventured to apply NGS technologies to identify 
sequence variations in known, but also in potentially new, candidate genes for lysosomal 
storage disorders. Among the first publications of an extensive research panel for the 
identification of LSDs was the study by Di Fruscio et al. in 2015 aiming to detect DNA 
sequence variation in the autophagy-lysosomal pathway.
16
 The autophagy-lysosomal pathway 
regulates cell homeostasis and plays an important role in lysosomal storage disorders and 
common neurodegenerative diseases.
17
 The authors developed Lysoplex, a targeted NGS 
approach enabling the parallel analysis of 891 genes involved in lysosomal (194 genes), 
endocytic (627 genes) and autophagic (106 genes) pathways. Lysoplex was successfully 
validated on 14 different types of LSDs and used to analyze 48 patients with unknown 
mutations and a clinical phenotype of neuronal ceroid lipofuscinosis. The average coverage 
depths for 95% of the target sequences was 40X and for 80% of the target sequences 100X 
was achieved. With a training set of 16 genomic DNAs from patients affected by 14 different 
forms of LSDs (including MPSI, II, IIB, VI, Fabry disease, NPC1, MLD, Pompe disease 
among others), whose molecular diagnosis was already known except for 2 cases, Di Fruscio 
and coworkers were able to detect all of the previously known mutations and to identify 
disease-causing mutations in the two previously undiagnosed LSD patients.
16
 
The authors also demonstrate the efficacy of Lysoplex in the analysis of patients with 
unknown molecular defect with a clinical diagnosis of neuronal ceroid lipofuscinosis (NCL). 
The NCLs are a family of autosomal recessive neurodegenerative disorders that annually 
affect 1:100,000 live births worldwide. This family of diseases results from mutations in one 
of 14 different genes that share common clinical and pathological etiologies. Though the 
disease phenotypes may vary in their age and order of presentation, all typically include 
progressive visual deterioration and blindness, cognitive impairment, motor deficits and 
seizures. Advances have been made in genetic diagnosis and counseling for families. 
However, comprehensive treatment programs that delay or halt disease progression have been 
elusive. Current disease management is primarily targeted at controlling the symptoms rather 
than "curing" the disease.
18
 A definite molecular diagnosis in such patients is the prerequisite 
for the enrollment in ongoing and future therapeutic trials. Di Fruscio and coworkers analyzed 
48 individuals with the clinical diagnosis of NCL and detected in 29/48 patients homozygous 
or compound heterozygous variants in known NCL genes. In 3 additional cases only a single 
heterozygous variant in known NCL genes was found, postulating that the second variant was 
not detectable because of a deep intronic or a large copy number variation (overall detection 
rate of 67% for causative mutations in NCL genes). In addition, the research-based NGS 
approach allowed the identification of recessive mutations in three potential novel NCL 
candidate genes. However, further functional analyses and in vivo studies in animal models 
are needed to confirm the causative nature of those variants.
16
 
 
Clinical exome sequencing to detect LSDs 
In the last few years whole exome sequencing (WES) or whole genome sequencing (WGS) 
approaches have gained unlimited consideration as universal tests for the identification of 
most Mendelian disorders
19,20,21
 with the exceptions of those caused by complex structural 
variations. As a more focused alternative to WGS, WES has been demonstrated to be a cost-
effective solution with a higher throughput on coding sequences that favors the identification 
of novel disease genes. 
A recent publication demonstrates the complexity and clinical variability of LSDs, as well as 
the potential role of WES in exposing gaps in clinical knowledge due to the rarity of many of 
these diseases. Three siblings, between 40 and 60 years of age, developed severe osteolysis of 
bones in the hands and feet. Known skeletal dysplasia genes were sequenced, but no mutation 
found. WES eventually revealed deleterious mutations in the ASAH1 gene, causing acid 
ceramidase deficiency or Farber disease, which was confirmed by enzymatic testing.
22
 The 
patients did have „typical” symptoms of the disease in childhood, but they were so mild that 
an LSD was not suspected. These became the oldest Farber disease patients ever diagnosed 
(by 40 years!). In addition, the ASAH1 gene can now be added to those tested in patients with 
osteolysis. 
 
Discussion 
Recent reports of the application of NGS technologies in the diagnosis of LSDs highlight the 
high clinical utility of gene panels in patients with clinical suspicion of lysosomal storage 
disorders and the potential to reduce diagnostic delay in a group of patients where a definitive 
diagnosis can be delayed for years. With decreasing sequencing costs and increasing 
availability of tests fulfilling guidelines for diagnostic NGS testing, there are several 
advantages of using gene panels early in the investigation of patients with LSDs. 
However, there are several issues raised by the application of hight-throughput sequencing 
that needs to be considered and harmonized across different laboratories. 
Since the technology and applications change constantly and rapidly, the available NGS 
platforms are not yet stable enough to ensure that all results obtained are equivalent. 
However, the technical variablity cannot hamper the implementation of NGS assays, only the 
implementation of insufficiently validated and poor quality tests should be prevented.
7
 Before 
implementing a diagnostic test, the aim of the assay should be clearly stated. It should be clear 
whether the test may be used to exclude a diagnosis, or to confirm a diagnosis. The 
’diagnostic yield’ of a test has to be certain before introducing an assay in the routine clinixcal 
diagnostic seting. The ’diagnostic yield’ refers to the chance that a disease-causing varinat is 
identified and a definitive molecular diagnosis can be made.
7
 The value should always refer to 
a patient cohort. This defines the performance of NGS from clinical point of view, and 
indicates the efficiency of the test. Currently, most laboratories offer their own selection of 
genes in the frame of a diagnostic gene panel. From the standpoint of the patients and medical 
practitioners, it would be important to harmonize genetic testing. For the diagnosis of LSDs it 
would make sense to have ’core disease gene lists’ established by clinical and laboratory 
experts of the field. Adding additional genes to standard core lists will increase the diagnostic 
yield, but it should not compromise the detection rate and the identification of disease-causing 
mutations. A simple rating system on the basis of coverage and diagnostic yield has already 
been proposed on behalf of EuroGentest and the ESHG,
7
 with a type A test offering >99% 
variant calls of the coding region and flanking intron sequences and fills all the gaps with 
Sanger-sequencing or another complementary analysis. Type B tests would clearly state 
which regions are sequenced at >99% reliable reference and fills some of the gaps with 
resequencing. Type C NGS tests only rely on the quality of NGS sequencing without offering 
additional resequencing. The ordering physician has to be fully informed about the limitations 
of the NGS assay, but also about the potential unanticipated effects of a particular type of 
genetic testing. Thus, the laboratory should specify the diseases not relevant to the clinical 
phenotype of the patient that could be caused by mutations in the tested genes. Especially in a 
broad panel of LSDs only a part of the analyzed genes will be relevant to the disease 
phenotype of the patient. However, heterozygous mutations in recessive conditions might be 
detected, leading to the unsought detection of disease carriers.
7
 This, in turn, can have 
consequences for counselling and reproductive choices. Laboratories, therefore, should 
provide information of the chance of unsolicited findings. 
 
A pitfall of using gene panels as first-tier analysis in the place of biochemical assays for 
identification of LSDs include the identification of variants of unknown significance (VUS) 
or Unclassified Variants (UVs or class 3 pathogenicity variants).
7,15
 The VUS rates will 
greatly vary from gene to gene, but large collaborative efforts to share variant data, such as 
ClinVar, disease-specific databases and other public databases are attemptimg to minimize 
this limitation.
23
 In patients harbouring a VUS, biochemical testing is essential to attempt to 
define the functional consequence of the sequence variant, however, this is not possible for 
pathologies that have no biochemical marker and in which confirmation will need to be 
obtained by other methods.
12
 Another important policy for laboratories is to set up a local 
variant database to manage disease variants and to collect data on VUS with the aim to 
eventually classify these variants definitively.
7
 
 
The detection of a single heterozygous mutation in a gene for an autosomal recessive disorder 
(as in most lysosomal storage disorders) and the limited performance of bioinformatic tools to 
detect deletions and duplications from targeted NGS data
15,24
 is another limitation 
encountered in the application of NGS assays in the diagnosis of LSDs. Currently, 
bioinformatic identification of deletions and duplications in many targeted NGS-based 
approaches is of limited sensitivity, especially for fewer than three exons.
24
 
 
Due to the characteristics of the technology, NGS also creates uncertainties and limitations of 
an order never encountered before in genetic testing. Uncertainties in genetic testing have 
always been existed, and this prompts us to constantly develop new tools to deal with those 
issues. Targeted NGS assays can have a role as support genetic tools in the diagnosis of 
lysosomal storage disorders always in combination with biochemical and clinical data. NGS 
assays have proven to be very powerful for making diagnoses that are particularly 
challenging, e.g. due to an atypical or late-onset presentation. Another strength of the method 
is to bring diagnostic odysseys to a more rapid conclusion than with approaches used 
previously. 
 
The pilot study of Fernandez-Marmiesse et al
12
 ended with 40 patients out of the 84 analyzed 
probands still undiagnosed, although it must be stated that 64% of these patients had a low or 
moderate index of suspicion of LSD. The considerable phenotypic overlap between certain 
LSDs and non-LSD neurometabolic or neurodevelopmental conditions pose a great limitation 
to the application of targeted NGS panels with genes specific only for LSDs. To address this 
problem several approaches are being used. The application of broad-range genetic panels that 
encompass most known neurometabolic disorders
12
 or the application of the Mendeliome, an 
NGS panel encompassing all known genes for Mendelian disorders
25
 might be a solution to 
enhance the detection rate in those patient groups. On the other hand, many reports already 
underline the diagnostic use of whole-exome sequencing as an ultimate test and the 
subsequent application of virtual panels in the stepwise diagnostic process of monogenic 
disorders with phenotypic and genetic heterogeneity.
19,20,21
 
 
Conclusions 
Genetic analysis has not been the primary screening tool used in the diagnosis of LSDs due to 
the cost and time requirements of the sequential genetic tests necessary to diagnose most of 
the disorders.
10,12
 However, with the wide availability of NGS technologies, a genetically 
based diagnosis can be established in 4-6 weeks, while providing cost reductions compared to 
the sequential Sanger sequencing of several single genes. Although the advantages of 
applying NGS in the diagnosis of LSDs are numerous, validation of a genetic diagnosis often 
still needs biochemical testing to confirm the functional consequences of a sequence variant. 
Given that NGS can be applied in a way that takes into account the many issues raised by 
international consensus guidelines, it can have an important role in the diagnostic process of 
lysosomal storage disorders. We emphasize the importance of a precise molecular genetic 
diagnosis early in the disease course of patients affected by LSDs, particularly as new 
therapies are becoming available for patients who share specific types of mutations. Further 
significance of NGS technologies in establishing a genetic diagnosis in patients, is due to the 
benefit derived by the opportunity for genetic counseling, family planning and the individual 
choice of reproductive options (including preimplantation genetic diagnosis) for affected 
families. It will be imperative to continually optimize this powerful technology with the 
potential benefits of patients and their families in mind. 
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